Articles tagged with Erk Signaling
A new drug targeting RAS, a pathologically altered protein causing 40% of colorectal and 90% of pancreatic cancers, has been developed. The molecular eraser, RIBOTAC, stops the production of RAS by degrading its mRNA, but surprisingly triggers changes in cancer cells despite minimal impact on protein quantity.
A team of researchers at Kyoto University has discovered that the protein ZO-1 plays a crucial role in collective cell migration by riding ERK activation waves to podosomes on the basal cell surface. This movement enhances force generation, extracellular matrix degradation, and invasive cell migration.
Researchers identify bone-forming cells as driver of scoliosis caused by NF1. Blocking RAS-MAPK signaling pathway with medications halts progression of spinal deformity in genetically engineered mouse model.
Early gastric cancer cells become self-sufficient by producing WNT7B, creating a self-sustaining loop and activating WNT signaling internally. This mechanism is triggered by MAPK signaling activation and has been validated in genetically engineered mouse models and human patient-derived organoids.
A specific protein, RASH3D19, activates the RAS signaling pathway involved in aggressive tumor growth and resistance to KRAS inhibitors. Blocking RASH3D19 improves outcomes in preclinical models, suggesting a potential therapeutic strategy.
A study from The University of Osaka reveals nearly half of patients with extracranial arteriovenous malformations carry mutations in the RAS/RAF/MAPK signaling pathway. These mutations were linked to abnormal vascular morphology and were frequently detected in younger female patients.
Researchers at University of Pittsburgh developed a new treatment approach for anthrax by reactivating the ERK pathway with a combination of growth factors. This method shows promise for treating the disease beyond its typical point of no return, offering hope for patients diagnosed late in the illness.
The study reveals that the interplay between ERK/MAPK and IFN-gamma signaling is essential for preserving intestinal stem cells during aging. The researchers found that maintaining a balance between these signaling pathways is critical for supporting stem cell maintenance, while also driving age-related changes in differentiated cells.
Researchers explore Extracellular signal-regulated kinase 5 (Erk5) and its unique structures regulating autophosphorylation and transcription. Erk5 is involved in angiogenesis, neurogenesis, energy metabolism, tumor growth, and metastasis, making it a potential target for cancer treatment.
Research found that RAMP1 protects liver cells from damage caused by ischemia-reperfusion injury. The protein inhibited the ERK/YAP pathway, leading to reduced cell death and inflammation. This study highlights RAMP1's potential as a therapeutic target for treating this condition.
New findings in The American Journal of Pathology indicate that periostin promotes esophageal squamous cell carcinoma progression by enhancing cancer and stromal cell migration in cancer-associated fibroblasts. Periostin may be a promising therapeutic target for treating ESCC.
Researchers discovered a new role for extracellular signal-regulated kinase (ERK) in a pathway activated by interferon-gamma that leads to cancer cell death. Hyperactivation of ERK causes stress in cells, triggering cell death through specific proteins DR5 and NOXA.
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
Researchers at EMBL Grenoble have obtained the first structure of p38α being activated by MKK6, opening up new directions for developing drugs to stop cytokine storms. The inflammatory response is triggered by a series of kinases, and inactivating p38α could prevent inflammation from occurring.
Research identifies key molecular signatures and pathways contributing to skeletal muscle strength loss in females with estrogen deficiency. The study found parallel patterns of inhibition and activation across various signaling pathways, including AMPK and calcium signaling.
Researchers have found that injuries on one part of an organism can trigger a whole-body response aiding wound healing and tissue regeneration. This coordination is crucial for successful regeneration in certain organisms such as planarians, zebrafish, and axolotls.
Researchers found that MALAT1 inhibition decreased BRAF RNA and protein levels, while increasing correlation with MAPK-associated genes. MALAT1-ASO treatment also reduced melanoma cell growth and tumor size in xenograft models.
Researchers discovered ERK signalling is a crucial switch between scarring and regeneration, with prolonged activation promoting regenerative success. Modulating ERK activity could potentially stimulate regeneration in clinical settings.
Researchers found a partial response in a patient with pancreatic acinar cell carcinoma, as well as stable disease in 11 patients, when combining riluzole with sorafenib in a phase I trial. The combination was safe and tolerable, and further exploration of its potential is warranted.
Researchers identify the minimum contribution of TACC3 for FGFR3-TACC3 fusion protein activation, revealing a novel target for treating FGFR translocation-driven cancers. The study shows that clinically identified FGFR3-TACC3 fusion proteins differ in biological activity depending on specific breakpoints.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
A team of researchers identified a protein kinase substrate downstream of the dopamine signaling pathway regulating brain reward behavior. The study found that phosphorylation of potassium voltage-gated channel subfamily Q member 2 (KCNQ2) decreases its channel activity, increasing neuronal excitability and promoting reward behavior.
Researchers found that genetic mutations in the MAPK pathway, key to normal cell growth, can also make head and neck cancer vulnerable. Individualized genomic analysis can identify specific mutations and target drugs, offering a promising approach to precision medicine.
Biomed Valley Discoveries will present four posters on ulixertinib (BVD-523), a first-in-class ERK1/2 inhibitor, at the AACR Annual Meeting 2022. The presentations focus on ulixertinib's potential in combating acquired resistance to the drug and its efficacy in combination with other therapies.
The newly developed KANPHOS database provides comprehensive information on kinase-associated protein phosphorylation, facilitating research into neural signaling pathways. The database contains information on phosphoproteins, phosphorylation sites, and participant kinases, allowing for searches based on various parameters.
Researchers around Christian Schröter and Luis Morelli have discovered that ERK activity pulses every six to seven minutes in living stem cells, encoding differentiation information. This intermittent oscillation is believed to be a morse code-like mechanism that helps stem cells make decisions about fate.
Researchers at Kyoto University discovered a novel method of communication among cells using 'mechano-chemical' signals. The findings show that the movement of one cell can trigger a cascading reaction resulting in collective cell migration.
Researchers have discovered a new mechanism by which cells respond to environmental stresses, including high temperature, dryness and high salination. The study found that a cytoplasmic sensor enhances MAP kinase phosphorylation, leading to a more accurate and robust response than previously thought possible.
Researchers have discovered that protein clumps, particularly pα-syn*, recruit enzymes and tau to damage brain cells, leading to mitochondrial destruction. This study provides insight into the molecular mechanisms of Parkinson's disease, shedding light on potential treatment targets.
The Mek5/Erk5 pathway plays a crucial role in skeletogenesis through the regulation of mesenchymal stem cell differentiation and chondrocyte maturation. Erk5 controls early chondrogenic differentiation and chondrogenic differentiation after condensation formation. This study improves our understanding of skeletal development and paves ...
Researchers at University of Helsinki have identified a key regulator of kidney development, revealing how MAPK activity influences nephron number in mature kidneys. This discovery holds promise for developing stem cell-based regenerative therapies as novel treatments for renal diseases.
Researchers used single-cell imaging to study how melanoma cells evade drug action and acquire resistance to BRAF-inhibitor dabrafenib. The study found that 10% of treated cells reactivated the MAPK signaling pathway within 2-3 days, allowing them to signal through the pathway even in the presence of BRAF inhibition.
A new study identifies a specific chain of proteins activated during barnacle metamorphosis, suggesting bacteria play a crucial role in their development. The findings could lead to the development of ship coatings that inhibit bacterial cues, mitigating biofouling issues.
Research found ginsenoside Rb1 enhances PI3K/Akt and MAPK signaling pathways, promoting neuronal survival and neurite growth in the hippocampus. The study suggests potential anti-dementia effects of ginsenoside Rb1 in Alzheimer's disease.
Activation of extracellular signal-regulated kinase 1/2 was shown to protect against hippocampal neuronal injury in a rat model of diabetic cerebral ischemia. However, reduced extracellular signal-regulated kinase 1/2 decreased Ku70 activity and increased Bax expression, leading to increased lost hippocampal neurons.
Researchers have identified a critical molecular pathway, the ERK pathway, that determines whether an adult cell can be reprogrammed and aid in limb regeneration. Constantly active ERK pathway may unlock new therapies for human diseases.
A team of researchers found that differences in response kinetics dictate differential sensitivity to different features of pulsatile hormone inputs. The study explored the mechanism underlying dynamic gonadotropin-releasing hormone (GnRH) signalling using live cell imaging and mathematical modelling.
A new study published in Clinical Cancer Research has found a dual-pronged strategy of combining two experimental cancer drugs to be an effective treatment for childhood cancer rhabdomyosarcoma. The study showed that the combination of AZD8055 and AZD6244 reduced tumour growth and blocked off escape routes, leading to improved outcomes.
Researchers at GIS and MPIMG discovered a molecular network in human embryonic stem cells that activates the ERK pathway, causing cells to respond by activating genetic information. The network also silences genetic information through ELK1, maintaining the cell's undifferentiated state.
Researchers have discovered that protein Shc acts as a tumor suppressor by binding to and blocking the activation of cancer-promoting protein Erk. This finding has significant implications for treating various types of cancer, including ovarian and prostate cancer.
Researchers used transgenic mice to study the effects of RAS pathway alterations on lymphatic system development. They found that excess ERK activation leads to lymphatic defects in RASopathies, which can be reversed by ERK inhibitor treatment.
Research at RIKEN Research Center for Allergy and Immunology reveals ERK signaling pathway's role in B cell differentiation into antibody-producing plasma cells. The finding could lead to breakthroughs in drug discovery for autoimmune diseases and allergies.
New study provides clearer picture of cellular signals contributing to aortic aneurysm progression in Marfan syndrome. Losartan alters these signals by blocking TGF-beta's partner, angiotensin II receptor.
Researchers at UNC Chapel Hill pinpointed Erk as crucial for nerve fiber insulation with myelin, allowing signals to be sent between brain and limbs. This discovery informs study of neurodevelopmental disorders like neurofibromatosis, where Schwann cells grow unregulated.
A study challenges the prevailing belief that a key human protein linked to cancer needs a partner to function, revealing it can initiate processes on its own. The researchers used high-resolution microscopy techniques to observe proteins in living cells and found that the protein's activation rate is directly linked to its nuclear entry.
Researchers at Case Western Reserve University have discovered a link between a genetic pathway and autism, finding that mutations in this pathway are associated with both autism and other developmental disorders. The study suggests that the lack of specific genes may play a role in the development of autism.
Researchers found that steady blood flow creates frictional force and stretching force that protect blood vessels from atherosclerosis. The study identified proteins involved in this process, including PECAM-1 and Fyn, which could lead to the development of new therapies.
Simultaneous inhibition of two signaling pathways, mTOR and MAPK, resulted in enhanced antitumor effects in mouse models of prostate and breast cancer. This combination therapy may improve the treatment of human cancers, particularly for patients with advanced, hormone-refractory prostate cancer.
Researchers found that simultaneously inhibiting the mTOR and MAPK signaling pathways enhanced antitumor effects in mouse models of prostate and breast cancer. This dual inhibition was particularly effective against aggressive forms of the disease, leading to a potential breakthrough for combination therapy.
Scientists at Jefferson University have found a new molecular evidence of the role of prolactin in breast cancer. The hormone stimulates a signaling pathway that may regulate the growth and survival of breast cancer cells. Inhibiting the Jak1 protein could represent a new drug target for treating breast cancer.
Researchers created a mouse model of EDMD to investigate gene expression changes in the heart. They found increased expression of MAP kinases, which play roles in other forms of cardiomyopathy. This discovery opens possibilities for treating lamin-related cardiomyopathies with MAP kinase inhibitors.
A team of researchers found that impaired Kv4.2 ion channels in neurons can lead to increased excitability and seizure frequency in epilepsy. Inhibiting the ERK enzyme may provide a new therapeutic target for treating this condition.
Researchers have discovered a new inhibitor called hSef, which regulates the Ras/ERK MAP kinase cascade by limiting ERK activity to specific regions of the cell. This discovery provides insights into how cellular signals are localized and controlled within the cell.
The MAP kinase pathway is activated in response to coxsackievirus infection, leading to increased viral replication. This signaling cascade also triggers host cell responses, including inflammation and immune activation.
Researchers found Yersinia pestis uses a protein called YopJ to cut off cellular communication, disrupting immune response and killing the host. Understanding this mechanism could have important implications in medicine, particularly for cancer and immune-related diseases.
Scientists at Harvard Medical School have discovered that a member of the MAP kinase family, ERK, may act as a molecular gatekeeper activating excitotoxic pathways. This finding could lead to new drug targets against stroke and other neurodegenerative diseases.